King-Jones Heidy

Reported to SECin USFilings at 1 company

No score on this page, by design. These filings come from the American register (SEC). We show them as facts, with what the share price did since each filing and since each trade; our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent filings by this filer, out of 9. Reading the whole list, and the full version of the page each row opens (that page itself opens free, with its first rows), is part of the subscription. So are this filer’s key figures and the price change beside each line, since the filing and since the trade. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first. Reported is the day the filing reached the regulator, usually a few days after the trade itself.

5 of 9
Reported insider transactions
CompanyTypeValueReportedCompanyValueTypeSharesReported
Spyre Therapeutics, Inc.See RemarksOption exercisenothing paid400 sharesSep 3, 2026Spyre Therapeutics, Inc.See Remarksnothing paidExercise · Sep 3Option exercise400Sep 3, 2026
Spyre Therapeutics, Inc.See RemarksOption exercisenothing paid27,999 sharesSep 3, 2026Spyre Therapeutics, Inc.See Remarksnothing paidExercise · Sep 3Option exercise27,999Sep 3, 2026
Spyre Therapeutics, Inc.See RemarksOpen-market sell$36,000400 sharesSep 3, 2026Spyre Therapeutics, Inc.See Remarks$36,000Sell · Sep 3Open-market sell400Sep 3, 2026
Spyre Therapeutics, Inc.See RemarksOption exercise$5,800400 sharesSep 3, 2026Spyre Therapeutics, Inc.See Remarks$5,800Exercise · Sep 3Option exercise400Sep 3, 2026
Spyre Therapeutics, Inc.See RemarksOpen-market sell$35,752400 sharesSep 3, 2026Spyre Therapeutics, Inc.See Remarks$35,752Sell · Sep 3Open-market sell400Sep 3, 2026